Hes a former NCAA Division I wrestler and a self-described meathead in the gym, but with a focus on health. He cautions: I would never personally take or suggest anyone take any of these peptides without clear clinical evidence for benefit in treating a disease, he says
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Hair Regrowth (Emerging) GHK-Cu is being investigated for hair follicle stimulation , especially when combined with microneedling or PRP
How It Works Tesamorelin is an FDA-approved GHRH analog that has been demonstrated in randomized controlled trials to significantly reduce visceral adipose tissue (the metabolically dangerous fat that accumulates around your organs)
Mechanistic research focuses on nitric oxide signaling, vascular homeostasis, cellular-membrane stability, and tissue responses to chemically induced injury
They are unapproved drugs
